Memantine Hydrochloride Tablet
Product Images NDC 50090-5832

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 50090-5832). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500905832)

Memantine Hydrochloride 10 mg oral tablets packaging label from A-S Medication Solutions. The label indicates 90 coated tablets with each containing 10 mg of Memantine Hydrochloride. Storage instructions specify keeping the product at 68 to 77 degrees Fahrenheit. The labeler is located in Libertyville, Illinois.*

FDA Label Image

Figure1 (Memantine Hydrochloride Tablets Figure1)

Chemical structure of Memantine Hydrochloride depicted as a three-dimensional skeletal formula showing the arrangement of nitrogen, carbon, and hydrogen atoms, including the hydrochloride component (HCl). This structure corresponds to the active ingredient Memantine Hydrochloride.*

FDA Label Image

Figure2 (Memantine Hydrochloride Tablets Figure2)

A line graph showing the mean (± SEM) change from baseline in ADCS-ADL score over 28 weeks of treatment. It compares Placebo and Memantine Hydrochloride Tablet groups, illustrating clinical improvement and decline trends, with time on the x-axis and score change on the y-axis.*

FDA Label Image

Figure3 (Memantine Hydrochloride Tablets Figure3)

A cumulative percentage of patients chart showing ADCS-ADL change from baseline for Memantine Hydrochloride Tablet and Placebo groups. The graph plots the cumulative percentage of patients on the vertical axis against change scores on the horizontal axis, with separate lines for Memantine Hydrochloride Tablet and Placebo, illustrating their comparative response distributions.*

FDA Label Image

Figure4 (Memantine Hydrochloride Tablets Figure4)

A line graph comparing the mean change from baseline in SIB score over 28 weeks of treatment between Memantine Hydrochloride Tablet and placebo groups. The x-axis represents weeks of treatment from 0 to 28, and the y-axis shows mean change with error bars. The placebo group shows a steady decline, while the Memantine Hydrochloride group remains near baseline, indicating differing trends in clinical outcomes.*

FDA Label Image

Figure5 (Memantine Hydrochloride Tablets Figure5)

A cumulative percentage of patients chart showing SIB change from baseline, comparing Placebo and Memantine Hydrochloride Tablet. The x-axis represents SIB change from baseline, and the y-axis shows the cumulative percentage of patients, with distinct curves for Placebo and Memantine Hydrochloride Tablet groups.*

FDA Label Image

Figure6 (Memantine Hydrochloride Tablets Figure6)

A line graph showing mean change from baseline in ADCS-ADL score over 24 weeks of treatment. Two groups are compared: Placebo/Donepezil and Memantine Hydrochloride Tablet/Donepezil, with error bars representing SEM. The graph indicates clinical improvement and decline thresholds.*

FDA Label Image

Figure7 (Memantine Hydrochloride Tablets Figure7)

A cumulative percentage of patients line graph showing ADCS-ADL change from baseline on the horizontal axis and percentage of patients on the vertical axis. The chart compares two treatment groups: Placebo/Donepezil and Memantine Hydrochloride Tablet/Donepezil, with distinct lines representing each group over the change range.*

FDA Label Image

Figure8 (Memantine Hydrochloride Tablets Figure8)

A line graph showing mean (± SEM) change from baseline in SIB score over 24 weeks of treatment. The x-axis represents weeks of treatment from 0 to 24, and the y-axis shows change in score from -4 to 4, with lines indicating clinical improvement (positive values) and clinical decline (negative values). Two treatment groups are plotted: Placebo/Donepezil (square markers) showing near baseline with decline at 24 weeks, and Memantine Hydrochloride Tablet/Donepezil (circle markers) showing an increase peaking around week 12 then declining but remaining above baseline.*

FDA Label Image

Figure9 (Memantine Hydrochloride Tablets Figure9)

A cumulative percentage curve graph showing patient response contrast between Placebo/Donepezil and Memantine Hydrochloride Tablet/Donepezil groups. The x-axis represents SIB (Severe Impairment Battery) Change from Baseline and the y-axis shows the Cumulative Percentage of Patients. Two distinct curves visualize comparative patient distributions over the SIB score changes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.